Nature Reviews Drug Discovery contents October 2015 Volume 14 Number 10 pp 663-732

If you are unable to see the message below, click here to view.

Advertisement
WHITE PAPER: Accelerate Drug Development with Model Repositories  Technology advances make custom GEM models easier to generate than ever. But, do you need to? It can prove more advantageous to recover existing GEMS from repositories that have already been phenotyped.  >> Download This Paper To Learn: How to find the models you need When to and when not to use repositories A listing of specialist repository collections worldwide >>Download Your Copy Today
TABLE OF CONTENTS
October 2015 Volume 14 Number 10		Advertisement
Impact Factor 41.908 *	In this issue Comment News and Analysis Research Highlights Reviews Also this month  Featured article: Zebrafish as tools for drug discovery Calum A. MacRae & Randall T. Peterson	nature.com webcasts Join us for our upcoming webcast with live Q&A: INNOVATIONS IN REGENERATIVE MEDICINE & CURATIVE BIOLOGICS Presented by BioPharma Dealmakers Date: Wednesday, October 14, 2015 Time: 8am PDT, 11am EDT, 4pm BST and 5pm CEST REGISTER FOR FREE Sponsored by: co.don, Asterias Biotherapeutics, SIWA Regenerative Medicine Corporation, Organovo
Subscribe   Facebook   RSS   Recommend to library   Twitter
Advertisement
BIOPHARMA DEALMAKERS Company Profiles and Partnering Opportunities
Advertisement
Nature Plants: Call for Papers Nature Plants launched in January and covers all aspects of plants be it their evolution, genetics, development or metabolism, their interactions with the environment, or their societal significance. The journal welcomes high quality submissions and encourages you and your colleagues to consider submitting your next research paper to the journal.  Submit your next research paper to the journal.
Advertisement
Nature Publishing Group presents a custom webcast on: Therapeutic and diagnostic activities of non-natural nucleosides to enhance cancer treatment Date: October 8, 2015 Time: 8am PDT / 11am EDT / 4pm BST / 5pm CEST  Register for the webcast and live Q & A session Sponsored by: EMD Millipore
Comment: Why is it hard to terminate failing projects in pharmaceutical R&D? Richard W. Peck, Dennis W. Lendrem, Iain Grant, B. Clare Lendrem & John D. Isaacs p663 | doi:10.1038/nrd4725 'Quick-kill' strategies in pharmaceutical research and development aim to reduce late-stage attrition by bringing project termination decisions forward, to an earlier point in the process. How can the barriers to implementing such strategies be overcome? Abstract | Full Text | PDF
NEWS AND ANALYSIS		Top
Heart drug pushes outcome-based pricing plans Melanie Senior p665 | doi:10.1038/nrd4741 Novartis' newly approved heart failure therapy Entresto could set precedents by bringing outcome-based pricing for a primary care drug to the United States. PDF
Cancer drug developers counteract kinase gatekeeper mutations Asher Mullard p667 | doi:10.1038/nrd4742 AstraZeneca and Clovis Oncology have submitted their next-generation EGFR kinase inhibitors for regulatory review. PDF
NEWS IN BRIEF FDA approves ultra-orphan drug on a 4-patient trial Asher Mullard p669 | doi:10.1038/nrd4756 PDF
FDA approves female sexual dysfunction drug Asher Mullard p669 | doi:10.1038/nrd4757 PDF
Off-label targeted cancer drugs fail in first randomized trial Asher Mullard p669 | doi:10.1038/nrd4758 PDF
BIOBUSINESS BRIEFS Regulatory watch: What drives differences in review times among CDER divisions? Andreas Schick, Kathleen L. Miller, Michael Lanthier & Janet Woodcock p670 | doi:10.1038/nrd4724 PDF
BIOBUSINESS BRIEFS Market watch: Upcoming market catalysts in Q4 2015 Michael Liu p671 | doi:10.1038/nrd4740 PDF
AN AUDIENCE WITH Francis Cuss p672 | doi:10.1038/nrd4748 Francis Cuss, Chief Scientific Officer of Bristol-Myers Squibb, discusses immuno-oncology, fibrosis and genetically defined diseases. PDF
FROM THE ANALYST'S COUCH The Alzheimer disease market XiaoXiao Qian, Bashar Hamad & Gus Dias-Lalcaca p675 | doi:10.1038/nrd4749 A number of potentially disease-modifying therapies are in late-stage clinical trials for Alzheimer disease (AD). This article discusses the different types of drugs in the AD drug pipeline and provides an outlook of their market potential. PDF
RESEARCH HIGHLIGHTS Top Bone diseases: Targeting myostatin for direct joint defence p677 | doi:10.1038/nrd4745 PDF Inflammatory diseases: Hydrogel drug delivery for inflammatory bowel disease p678 | doi:10.1038/nrd4744 PDF Infectious diseases: Vaccine for Middle East respiratory syndrome p678 | doi:10.1038/nrd4746 PDF Prion diseases: Polythiophenes delay prion-induced neurodegeneration p679 | doi:10.1038/nrd4743 PDF Cancer: Small-molecule FGF trap shrinks tumours p680 | doi:10.1038/nrd4747 PDF IN BRIEF Cancer: Polytherapy for lung cancer | Regenerative medicine: Automated production of iPSCs | Influenza: Towards a universal vaccine PDF Drug Discovery JOBS of the week Two Postdoctoral Positions within Drug Discovery and Protein Biochemistry University of Copenhagen Postdoctoral Researcher (RNA)-targeted drug discovery University of the Sciences in Philadelphia Postdoctoral Researcher (RNA)Targeted Drug Discovery University of the Sciences Postdoctoral Positions in Biomolecular Simulations & Drug Discovery UNT Health Science Center More Science jobs from Drug Discovery EVENT 5th Drug Formulation, Solubility & Bioavailability Summit 25.01.1 Philadelphia, USA More science events from
Advertisement
Automated Protein Sample Prep Shimadzu's Perfinity Workstation automates key proteomics workflow steps to significantly reduce sample preparation times and enhance reproducibility, making it the ideal solution for improving time-consuming, user-dependent protein sample prep workflows for LC-MS/MS. Learn more.
REVIEWS		Top
Current status of pluripotent stem cells: moving the first therapies to the clinic Erin A. Kimbrel & Robert Lanza p681 | doi:10.1038/nrd4738 Human pluripotent stem cells are being developed for therapeutic use in numerous conditions that affect different organs. In this Review, Kimbrel and Lanza discuss the history and science behind the approach and provide an overview of the products that are in clinical development or close to clinical development. Abstract | Full Text | PDF
Dissecting fibrosis: therapeutic insights from the small-molecule toolbox Carmel B. Nanthakumar, Richard J. D. Hatley, Seble Lemma, Jack Gauldie, Richard P. Marshall & Simon J. F. Macdonald p693 | doi:10.1038/nrd4592 Fibrosis is a common but often debilitating pathological process involved in diseases of different tissues. Here, Macdonald and colleagues describe the common features and pathophysiological processes that lead to fibrosis of different organs, and present a 'fibrosis toolbox': a collection of small molecules that can be used to further dissect the pathogenesis of tissue fibrosis. Abstract | Full Text | PDF | Supplementary information
Zebrafish as tools for drug discovery Calum A. MacRae & Randall T. Peterson p721 | doi:10.1038/nrd4627 The zebrafish, a well-established model organism in basic biomedical research, has also become tractable for numerous applications in drug discovery, from phenotypic screens to testing for toxicity. In this Review, MacRae and Peterson discuss how zebrafish have been used in such applications, advances that could make it an increasingly attractive tool — particularly for phenotypic screening — and the challenges that need to be addressed. Abstract | Full Text | PDF
Advertisement
Droplet Digital™ PCR (ddPCR™) is leading the way  From tracking cancer biomarkers to quantifying rare mutations, gene editing events, and miniscule viral loads, Droplet Digital PCR has led to more discoveries than any other digital PCR platform. Visit our ddPCR page for application guides, publication lists, and webinars that explore the world of Droplet Digital PCR.  Learn more
Corrigendum: Unleashing the therapeutic potential of human kallikrein-related serine proteases Ioannis Prassas, Azza Eissa, Gennadiy Poda & Eleftherios P. Diamandis p732 | doi:10.1038/nrd4726 Full Text | PDF
Advertisement
Primers in your inbox Nature Reviews Disease Primers launched in April 2015 and publishes Primers — introductory review articles that provide overviews of diseases and disorders. Primer articles describe all aspects of a condition: epidemiology; disease mechanisms; diagnosis, screening and prevention; management; and quality of life.  Stay updated on the latest Primers published.
Natureevents is a fully searchable, multi-disciplinary database designed to maximise exposure for events organisers. The contents of the Natureevents Directory are now live. The digital version is available here. Find the latest scientific conferences, courses, meetings and symposia on natureevents.com. For event advertising opportunities across the Nature Publishing Group portfolio please contact natureevents@nature.com More Nature Events

*2013 Journal Citation Report (Thomson Reuters, 2014)

You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/myaccount (You will need to log in to be recognised as a nature.com registrant). For further technical assistance, please contact our registration department For print subscription enquiries, please contact our subscription department For other enquiries, please contact our feedback department Nature Publishing Group | One New York Plaza, Suite 4500 | New York | NY 10004-1562 | USA Nature Publishing Group's worldwide offices: London - Paris - Munich - New Delhi - Tokyo - Melbourne San Diego - San Francisco - Washington - New York - Boston Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at Brunel Road, Houndmills, Basingstoke, Hampshire RG21 6XS. © 2015 Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.